Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Lee's Pharmaceutical Holdings's Shareholder Yield % was -2.30%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Lee's Pharmaceutical Holdings Shareholder Yield % Related Terms
Lee's Pharmaceutical Holdings Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LPCUF vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Lee's Pharmaceutical Holdings (LPCUF) has a Shareholder Yield % of -2.30% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Lee's Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #679 out of 973 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Lee's Pharmaceutical Holdings' Shareholder Yield % too high?
Lee's Pharmaceutical Holdings' current Shareholder Yield % is -2.30%. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #679 out of 973 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #679 out of 973 companies for Shareholder Yield %. This places Lee's Pharmaceutical Holdings in the lower half of its industry. The industry median Shareholder Yield % is 0.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current Shareholder Yield % is -2.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current Shareholder Yield % of -2.30%. The stock's GF Value™ is $0.30, compared to a current price of $0.19 — trading 36.6% below its estimated fair value. The current Shareholder Yield % is -2.30%. Lee's Pharmaceutical Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current Shareholder Yield % is -2.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of $0.19 is trading 36.6% below its estimated GF Value™ of $0.30.
Key valuation signals for LPCUF:
Shareholder Yield %: -2.30%
GF Value™: $0.30 vs. price of $0.19 (36.6% below fair value)
No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
72GF Score
Get the complete analysis for LPCUF
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCUF has been successfully added to your 
